2014
DOI: 10.1038/leu.2014.41
|View full text |Cite
|
Sign up to set email alerts
|

MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

17
793
0
5

Year Published

2016
2016
2020
2020

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 902 publications
(848 citation statements)
references
References 15 publications
17
793
0
5
Order By: Relevance
“…Fluorescence microscopy and flow cytometric analyses confirmed incorporation of eGFP into the N-KM cells (Figure 5(e)), implying that purified CD63-eGFP labelled EVs still retain their properties to be taken up by N-KM cells. Using the same protocol to prepare sEVs from supernatants of MSCs, we demonstrated that these MSC-EVs were able to exert therapeutic effects in different animal models and in a human GvHD patient [14,16,52,53]. Since these PEG-prepared sEV samples exerted the same therapeutic effects in a murine ischemic stroke model than corresponding MSCs [16], our results demonstrate the usability of the PEG-precipitation method as a scalable method for the enrichment of biologically active sEVs.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Fluorescence microscopy and flow cytometric analyses confirmed incorporation of eGFP into the N-KM cells (Figure 5(e)), implying that purified CD63-eGFP labelled EVs still retain their properties to be taken up by N-KM cells. Using the same protocol to prepare sEVs from supernatants of MSCs, we demonstrated that these MSC-EVs were able to exert therapeutic effects in different animal models and in a human GvHD patient [14,16,52,53]. Since these PEG-prepared sEV samples exerted the same therapeutic effects in a murine ischemic stroke model than corresponding MSCs [16], our results demonstrate the usability of the PEG-precipitation method as a scalable method for the enrichment of biologically active sEVs.…”
Section: Resultsmentioning
confidence: 99%
“…In proof of principle experiments, we show that sEVs prepared with the PEG method are effectively incorporated into target cells. Furthermore, we have successfully used the optimised PEG method to prepare sEV samples for the preclinical and clinical setting from several litres of MSC-conditioned media [14,16,52,53]. Upon comparing the therapeutic impacts of such MSC-EV samples with that of corresponding MSCs in a murine ischemic stroke model, we did not detect any functional difference [16].…”
Section: Discussionmentioning
confidence: 99%
“…One of the safety considerations is the use of animal free/bovine EV-free media. In that regard, our UF depletion protocol producing EV-free serum, which still supports EV production, could be applied to any sera including human serum, thus providing a good option for the future GMP production of EVs for clinical applications in regenerative medicine and therapy [10]. …”
Section: Discussionmentioning
confidence: 99%
“…For example, therapeutic activities in adipose-derived mesenchymal stem cells (AT-MSCs) are mediated by EVs along with other paracrine signalling routes [8,9]. The MSC EVs have a unique capability to induce regeneration of damaged tissues offering a paradigm shift towards cell-free therapy [10,11]. …”
Section: Introductionmentioning
confidence: 99%
“…This is an accepted approach to study EVs. Indeed, in one of the few exosome clinical applications reported, the therapeutic unit is described as “the EV fraction prepared from supernatants of 4 × 10 7 mesenchymal stem cells that had been conditioned for 48 h” [34]. We considered this approach as the most relevant in our context, in opposition to the regularly used normalization by protein quantification [8].…”
Section: Discussionmentioning
confidence: 99%